

Supervisory Board Members

Ferdinand Verdonck – Chairman

Mr. Verdonck is currently on the board of several companies. His professional experience is based on his work, mainly in financial services. Most recently as the managing director of Almanij and earlier with Lazard Frères and also in manufacturing (Bekaert NV). His responsibilities entailed board participation in publicly traded and privately held companies in many countries. He holds a law degree from the KU Leuven and degrees in economics from KU Leuven and the University of Chicago.

Nationality: Belgian; age: 67

Philippe Van Holle – Member

Mr. Van Holle is Head of Celgene Europe. He has 30 years of marketing and sales experience in the pharmaceutical and biotechnology industries. Most notably he was responsible at Amgen Europe for the commercial roll-out of Neupogen® and Epogen®, the two first biotech blockbuster products. Subsequently he served as an executive at Genzyme Europe, overseeing the commercialization of Genzyme's orphan drugs. In 2005, he joined Celgene as Head of Celgene Europe. Over the past few years Celgene has grown into the fourth largest biotechnology company worldwide with a market capitalization of approximately \$25 billion.

Nationality: Belgian; age: 55

Sander van Deventer - Member

Dr. van Deventer, one of AMT's co-founders, chairs AMT's Scientific Advisory Board. Dr. van Deventer holds a degree in Medicine as well as a Ph.D. from the University of Amsterdam. He was Professor and Head of the Department of Experimental Medicine, Chairman at the Department of Gastroenterology of the Academic Medical Center in Amsterdam from 2002 to 2004, and subsequently Professor of Experimental Medicine at the University of Amsterdam Medical School until 2008. He has over 15 years experience in biotechnology product development. He is the author of more than 350 scientific articles in peer-reviewed journals, and he serves as an advisor to regulatory authorities including the EMEA and FDA. Currently, he is Professor of Translational Gastroenterology at the Leiden University Medical Center (LUMC), and a partner of Forbion Capital Partners.

Nationality: Dutch; age: 55

Joseph M. Feczko - Member

Joseph Feczko was, until May, 2009, Senior Vice President and Chief Medical Officer (CMO) of Pfizer, Inc., and a member of the Executive Leadership Team with global responsibilities for all aspects of the company's medical, regulatory and safety activities. Following a time in private practice, he joined Pfizer in 1982 in New York. He then worked for ten years in the United Kingdom for both Pfizer and Glaxo where his responsibilities included supervising clinical research, regulatory affairs, data management and safety reporting. He returned to Pfizer in New York in 1996, where he held positions of increasing responsibility in clinical research, and regulatory affairs and safety, culminating in the role of CMO. Dr. Feczko is currently a member of the Board of Directors of the Foundation for the National Institutes of Health, Research!America, the International Longevity Center and the New York Academy of Medicine (all US). He is a member of the Board of Directors of the Accordia Global Health Foundation and the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health. He is also a member of the Governing Board of the Technology Strategy Board of the United Kingdom. He is currently Chairman of the Board of Directors of Cardoz Pharmaceuticals AB (Sweden), and a member of the Board of Directors of Keryx Biopharmaceuticals, Inc. (US). Dr. Feczko is board-certified in Internal Medicine and a specialist in Infectious Diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine.

Nationality: American; age: 62

François Meyer - Member

François Meyer was General Director for Research and Development at Aventis Pharma, France until 2002 and subsequently Director-General of Aventis' Gene Therapy Division, Gencell, until his retirement in 2006. He joined Gencell as Vice-President in 1996, within the Rhône-Poulenc Group, prior to the formation of Aventis when Rhone-Poulenc merged with Hoechst. He was promoted to Vice President of RPR Global Research in 1997, and Corporate Senior Vice President of Global Research in 1998. In 1992, Dr. Meyer joined Sandoz Pharma's gene and cell therapy business as Vice President, while he also served as a member of the company's Corporate Research Board. From 1989 to 1992, he was Director of Research at the CNRS. From 1980 - 1984, he built and headed the Molecular Genetics department in the newly formed Biotechnology division at Ciba-Geigy, where he was responsible for the discovery and production of new recombinant proteins.

Dr. Meyer is a member of the Board of Directors of BioSeek, Inc. (US), Introgen Therapeutics, Inc. (US), Gene Therapy, Inc. (US), and Urogene SA (France), and a member of the Scientific Advisory Boards of Genethon (France), Systemix, Inc. (US) and Biotransplant, Inc. (US). Dr. Meyer graduated from the Swiss Federal Institute of Technology (ETH), in Zurich, and studied Biochemistry and Molecular Biology at the University of Zurich. He received his Ph.D. from the Institute for Molecular Biology in 1978, and became a Senior Member at the Institute. During his career, Dr. Meyer has also served as a lecturer in Molecular Biology at the Swiss Federal Institute of Technology.

Nationality: French; age: 63